Harvard Bioscience (HBIO) Cash & Equivalents (2010 - 2026)

Harvard Bioscience (HBIO) has reported Cash & Equivalents for 17 consecutive years, with $7.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 27.98% year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $7.1 million (up 27.98% YoY), while the FY2025 annual figure was $8.6 million, up 109.69% from the prior year.
• Cash & Equivalents retreated to $7.1 million in Q1 2026 per HBIO's latest filing, from $8.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $8.6 million in Q4 2025 and bottomed at $3.8 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $5.3 million across 5 years, with a median of $4.6 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 42.36% — and 2025, when it jumped 109.69%.
• Harvard Bioscience's Cash & Equivalents stood at $4.5 million in 2022, then decreased by 4.99% to $4.3 million in 2023, then fell by 4.09% to $4.1 million in 2024, then surged by 109.69% to $8.6 million in 2025, then declined by 17.6% to $7.1 million in 2026.
• Business Quant data shows HBIO's Cash & Equivalents at $7.1 million in Q1 2026, $8.6 million in Q4 2025, and $6.8 million in Q3 2025.